Sanofi SAN-1.02 % decrease; red down pointing triangle agreed to buy Blueprint Medicines BPMC 0.04 % increase; green up pointing triangle for up to $9.5 billion, the French drugmaker’s biggest ...

Sanofi shares on Euronext Paris, however, dipped 1.8% from €87.52 ($99.85) to €85.91 ($98.18). Hudson also said that Sanofi still retained a “sizeable” capacity for further acquisitions.

Sanofi and Blueprint Medicines, a U.S.-based, publicly traded biopharmaceutical company specializing in systemic mastocytosis, a rare immunological disease, and other KIT-driven diseases, have ...

Sanofi shares fell 0.4 percent in Wall Street trading on Monday, while Blueprint’s soared more than 26 percent to $127.79 a share. Hudson shocked investors in 2023 when his research and ...

Sanofi's Focus On Alzheimer's Disease The companies expect the deal to close in the third quarter. In addition to the $470 million, Vigil shareholders will receive a contingent value right, or CVR ...

Sanofi will acquire Blueprint Medicines for up to $9.5 billion, gaining Ayvakit and a promising immunology pipeline, including BLU-808 and elenestinib. España Italia ...

Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on Dupixent. Read more about why SNY is still a Buy.

Morristown-based Sanofi will spend $20 billion on its U.S. operations through 2030. It also has a Massachusetts presence. Sanofi has roughly 1,900 employees in Morristown at the M Station ...

Sanofi last week closed its purchase of an early-stage immunology drug candidate from Dren Bio for up to $1.9 billion and in May agreed to acquire Vigil Neuroscience for about $470 million, adding ...